EDISON EQUITY RESEARCH : ATHERSYS
August 19 2015 - 10:30AM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH: ATHERSYS - MORE
CLARITY ON ISCHAEMIC STROKE
In its Q215 earnings release, Athersys provided much needed
additional
data with regard to its Phase II MultiStem trial in ischaemic
stroke, which
had missed the primary endpoint. Changes in the trial design aimed
at
accelerating enrolment led to the inclusion of patients both less
likely to
respond to MultiStem and more likely to respond to standard of
care. If the
original trial design had been in place, the additional data
suggest the trial
may have been positive. Our fair value increases to $256m or $3.09
per
share as we increase the probability of success to 25% from
20%.
Athersys is a US biotech company developing
MultiStem (allogeneic, bone marrow-derived stem
cells). A Phase II trial with MultiStem in ischaemic
stroke has completed, while further studies in AMI
(Phase II) and ARDS (Phase IIa) are planned.
To view our full report, please click here
Click here to view all of Edison Investment
Research’s published reports
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2023 to Apr 2024